强生、康乐卫士新药报产,诺诚健华1类新药纳入优先审评

医药经济报
23 Apr

2020年10月,康乐卫士启动了三价HPV疫苗的III期临床试验。2024年8月,该产品Ⅲ 期保护效力临床试验独立数据监察委员会(IDMC)已完成期中分析揭盲、主要疗效指标和安全性评估,结果符合预期。公开信息显示,康乐卫士已在昆明完成HPV疫苗产业化基地,设计年产能为三价HPV疫苗1000万剂和九价HPV疫苗3000万剂。诺诚健华卓乐替尼片拟纳入优先审评今日,CDE官网显示,诺诚健华申报的1类新药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10